Wall Street brokerages expect that Eagle Pharmaceuticals (NASDAQ:EGRX) will report earnings of $0.84 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals’ earnings. The highest EPS estimate is $1.11 and the lowest is $0.57. Eagle Pharmaceuticals posted earnings per share of $1.42 during the same quarter last year, which would suggest a negative year over year growth rate of 40.8%. The company is expected to issue its next quarterly earnings report on Monday, May 14th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $3.94 per share for the current fiscal year, with EPS estimates ranging from $3.81 to $4.06. For the next year, analysts expect that the firm will post earnings of $4.29 per share, with EPS estimates ranging from $4.05 to $4.53. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $1.00 by ($0.16). Eagle Pharmaceuticals had a net margin of 21.94% and a return on equity of 34.16%. The firm had revenue of $46.80 million during the quarter, compared to analyst estimates of $53.65 million. During the same period in the previous year, the firm posted $3.52 EPS. The company’s revenue for the quarter was down 42.3% compared to the same quarter last year.
Several research analysts recently weighed in on the stock. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 8th. Piper Jaffray restated a “buy” rating and issued a $79.00 price target on shares of Eagle Pharmaceuticals in a report on Tuesday, January 30th. Zacks Investment Research cut Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, Royal Bank of Canada set a $71.00 price target on Eagle Pharmaceuticals and gave the company a “buy” rating in a report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Eagle Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $63.33.
In other Eagle Pharmaceuticals news, Director Sander A. Flaum sold 2,340 shares of Eagle Pharmaceuticals stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total value of $126,219.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 19.50% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan grew its holdings in Eagle Pharmaceuticals by 68.1% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after buying an additional 1,300 shares during the period. Smith Asset Management Group LP purchased a new stake in Eagle Pharmaceuticals in the 4th quarter valued at about $187,000. Schroder Investment Management Group purchased a new stake in Eagle Pharmaceuticals in the 3rd quarter valued at about $219,000. Campbell Newman Asset Management Inc. purchased a new stake in Eagle Pharmaceuticals in the 4th quarter valued at about $200,000. Finally, MetLife Investment Advisors LLC purchased a new stake in Eagle Pharmaceuticals in the 4th quarter valued at about $218,000.
EGRX stock traded up $0.30 during trading on Thursday, hitting $52.41. The stock had a trading volume of 218,781 shares, compared to its average volume of 193,669. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $97.15. The company has a market capitalization of $774.46, a price-to-earnings ratio of 15.55 and a beta of 1.38. The company has a current ratio of 3.99, a quick ratio of 3.88 and a debt-to-equity ratio of 0.24.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/15/0-84-eps-expected-for-eagle-pharmaceuticals-egrx-this-quarter.html.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.